IL141025A0 - Lipid-lowering quinazoline derivative - Google Patents

Lipid-lowering quinazoline derivative

Info

Publication number
IL141025A0
IL141025A0 IL14102599A IL14102599A IL141025A0 IL 141025 A0 IL141025 A0 IL 141025A0 IL 14102599 A IL14102599 A IL 14102599A IL 14102599 A IL14102599 A IL 14102599A IL 141025 A0 IL141025 A0 IL 141025A0
Authority
IL
Israel
Prior art keywords
lowering
lipid
quinazoline derivative
cholesterol
carbonyl
Prior art date
Application number
IL14102599A
Other languages
English (en)
Original Assignee
Parker Hughes Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parker Hughes Inst filed Critical Parker Hughes Inst
Publication of IL141025A0 publication Critical patent/IL141025A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/74Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
IL14102599A 1998-07-30 1999-07-13 Lipid-lowering quinazoline derivative IL141025A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/126,940 US6172071B1 (en) 1998-07-30 1998-07-30 Lipid-lowering quinazoline derivative
PCT/US1999/015841 WO2000006554A1 (en) 1998-07-30 1999-07-13 Lipid-lowering quinazoline derivative

Publications (1)

Publication Number Publication Date
IL141025A0 true IL141025A0 (en) 2002-02-10

Family

ID=22427479

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14102599A IL141025A0 (en) 1998-07-30 1999-07-13 Lipid-lowering quinazoline derivative

Country Status (13)

Country Link
US (2) US6172071B1 (es)
EP (1) EP1100787B1 (es)
JP (1) JP2002521475A (es)
KR (1) KR20010089146A (es)
AT (1) ATE306476T1 (es)
AU (1) AU750653B2 (es)
CA (1) CA2338825A1 (es)
DE (1) DE69927689T2 (es)
HU (1) HUP0102887A2 (es)
IL (1) IL141025A0 (es)
MX (1) MXPA01001139A (es)
NO (1) NO20010525L (es)
WO (1) WO2000006554A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294532B1 (en) 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
US6410545B2 (en) 1998-07-30 2002-06-25 Parker Hughes Institute Lipid lowering quinazoline dietary supplement composition
PL205557B1 (pl) 1999-02-10 2010-05-31 Astrazeneca Ab Pochodne indolu
US6126917A (en) * 1999-06-01 2000-10-03 Hadasit Medical Research Services And Development Ltd. Epidermal growth factor receptor binding compounds for positron emission tomography
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
RU2362774C1 (ru) 2002-02-01 2009-07-27 Астразенека Аб Хиназолиновые соединения
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
WO2006034056A2 (en) * 2004-09-16 2006-03-30 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
US7579319B2 (en) * 2004-12-06 2009-08-25 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
CN104016929B (zh) * 2014-06-25 2016-03-30 北京理工大学 一种合成喹唑啉-4(3h)-酮的方法
FI3416684T3 (fi) * 2016-02-17 2023-07-31 Regeneron Pharma Menetelmiä ateroskleroosin hoitamiseksi tai ehkäisemiseksi antamalla ANGPTL3:n inhibiittoria

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative

Also Published As

Publication number Publication date
US20010008894A1 (en) 2001-07-19
NO20010525D0 (no) 2001-01-30
HUP0102887A2 (hu) 2003-02-28
AU750653B2 (en) 2002-07-25
DE69927689T2 (de) 2006-07-20
MXPA01001139A (es) 2002-04-24
WO2000006554A1 (en) 2000-02-10
DE69927689D1 (de) 2006-02-23
US6172071B1 (en) 2001-01-09
EP1100787A1 (en) 2001-05-23
ATE306476T1 (de) 2005-10-15
EP1100787B1 (en) 2005-10-12
KR20010089146A (ko) 2001-09-29
US6355645B2 (en) 2002-03-12
NO20010525L (no) 2001-01-30
CA2338825A1 (en) 2000-02-10
AU4991399A (en) 2000-02-21
JP2002521475A (ja) 2002-07-16

Similar Documents

Publication Publication Date Title
IL141025A0 (en) Lipid-lowering quinazoline derivative
EP1707563A3 (en) Methods and compositions utilizing quinazolinones
WO2002032893A3 (en) Piperidine compounds as anti-allergic
AU2002316459A1 (en) Methods of treating cytokine mediated diseases
CA2388646A1 (en) Methods and compositions utilizing quinazolinones
EP1450808B8 (en) Quinazoline derivatives for the treatment of t cell mediated diseases
AU2002313249A1 (en) Quinoline derivative and quinazoline derivate inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same
WO2001012606A3 (en) Tetrahydroquinoline derivatives having retinoid-like biological activity
MY129348A (en) Stable polymorph of n-(3-ethynylphenyl)-6, 7-bis (2-methoxyethoxy)-4- quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
WO1999054326A8 (de) Dihydropyrimidine
EE200200118A (et) Terapeutilised kinasoliini derivaadid, nende valmistamise meetod ning kasutamine
DE69613705D1 (de) Piperinderivate als neurokininantagoniste
WO2003020700A3 (en) SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF
CA2151674A1 (en) Methods of Administering CRF Antagonists
CA2330447A1 (en) N-(3-ethynylphenyl-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
AU2003228674A1 (en) Muscarinic antagonists
AU7839100A (en) Quinazolinones and analogues and their use as local anesthetics
WO2002083651A3 (en) Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
PL344042A1 (en) Compounds with growth hormone releasing properties
EP1254662A3 (en) Methods and kits for treating depression or preventing deterioration of cognitive function
AU9624198A (en) Quinoline and quinazoline derivatives having corticotropin releasing factor (crf) antagonist activity
EP1105407A4 (en) AMINOSTEROLIC COMPOUNDS AND USES THEREOF
AU4080097A (en) Piperazino derivatives as neurokinin antagonists
WO2000064423A3 (fr) Utilisation du saredutant et de ses sels pharmaceutiquement acceptables dans le traitement ou la prevention des troubles de l'humeur d'adaptation et de l'anxiete-depression
NZ335052A (en) Piperazino derivatives as neurokinin antagonists